Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder
International Clinical Psychopharmacology, 06/04/2012
Baldwin DS et al. – Lu AA21004 5 or 10 mg/day was efficacious in preventing relapse and was well tolerated in the maintenance treatment of generalized anxiety disorder.Methods
- Patients (n=687) with a primary diagnosis of GAD (DSM-IV criteria) and a baseline Hamilton Anxiety (HAM-A) total score of at least 20 underwent a 20-week, open-label Lu AA21004 treatment.
- In all, 459 patients responded and were randomized to 24–56 weeks of a double-blind treatment with Lu AA21004 (n=229) or placebo (n=230).
- The predefined primary efficacy endpoint was time to relapse (HAM-A total score ≥15) using a Cox model; the key secondary efficacy endpoint under multiplicity control was time to relapse for patients responding to treatment for at least 12 weeks.
- The primary analysis showed a statistically significant effect of Lu AA21004 relative to the placebo on the time to relapse of GAD, with a hazard ratio of 2.71 (P<0.001).
- There was a statistically significant effect of Lu AA21004 in the stable responders (hazard ratio=3.06, P<0.001).
- Lu AA21004 was well tolerated, with withdrawal rates due to adverse events of 9% (open-label) and 3% (placebo) and 4% (Lu AA21004) in the double-blind period.